Covaxin
-
Malvern’s Ocugen Prepping for $16.5 Million Stock Sale Weeks After Nixing Its COVID Vaccine
A Malvern-based biotechnology company known for its gene therapies and vaccines, is expecting to raise $16.5 million through a public stock offering, writes John George…
-
Positive Study Results in Children Further Malvern-Based Ocugen’s Hopes to Bring Its COVID-19 Vaccine to U.S.
Malvern-based Ocugen announced positive feedback for pediatric clinical testing of its version of the COVID-19 vaccine as the biopharmaceutical company attempts to bring it to…
-
Malvern-Based Ocugen’s Stock Soars After FDA Lifts Clinical Hold on New Drug Application for COVID Vaccine
Malvern-based Ocugen saw its stock soar after the FDA lifted its clinical hold on the company’s investigational new drug application to test the COVID-19 vaccine…
-
Malvern-Based Ocugen’s ‘Next Evolution of Business’: Buying Dormant Manufacturing Plant in Canada
Malvern-based Ocugen, which is working to bring the Covaxin COVID-19 vaccine to the U.S., has entered into a deal to buy a manufacturing plant in…
-
Malvern-based Ocugen Seeks FDA Emergency Use Authorization of Its COVID-19 Vaccine Use in Children
Malvern-based Ocugen has submitted a request to the Food and Drug Administration for Emergency Use Authorization (EUA) of its COVID-19 vaccine candidate for children. The…
-
Could a Fourth COVID-19 Vaccine Be on the Way, Thanks to a Company in Chester County?
Malvern-based Ocugen collaborated with India’s Bharat Biotech to develop a fourth vaccine, and it could be a game-changer in the ongoing fight against COVID-19, writes…
-
Done Deal: Malvern Company to Co-Develop COVID-19 Vaccine for U.S. Market
Malvern-based Ocugen has finalized a deal with Bharat Biotech to develop the India-based company’s COVID-19 vaccine, Covaxin, for the U.S. market, writes John George for…
-
Malvern-Based Ocugen’s Pandemic Pivot Boosts Its Stock Price by Nearly 800 Percent
The decision to expand beyond gene therapy and sign a deal to co-develop a COVID-19 vaccine has turned out well for Malvern-based Ocugen, writes John…
-
Malvern-Based Ocugen’s Stock Nearly Triples After Inking Pact to Co-Develop COVID-19 Vaccine
Malvern-based Ocugen saw its stock nearly triple last week after the company signed a letter of intent with Bharat Biotech to co-develop the India-based company’s…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
